Anemia in heart failure - A concise review

Clinical Cardiology

Volumn 28, Issue 10, 2005, Pages 454-458

  Vasu, Sujethra ^a   Kelly, Patricia ^a   Lawson, William E ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Anemia; Angiotensin II; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CD34 ANTIGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FOLIC ACID; IRON; LOSARTAN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ANEMIA; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; ERYTHROPOIESIS; HEART FAILURE; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STEM CELL;

EID: 26444465112     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960281003     Document Type: Review

References (32)

1. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Studies of Left Ventricular Dysfunction-SOLVD. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38(4):955-962
2. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R: Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 2002;13(7):1928-1936
3. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003;41(11):1933-1939
4. Harwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002-39(11):1780-1786
5. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107(2):223-225
6. Kalra PR, Bolger AP, Francis DP, Genth-Zotz S, Sharma R, Ponikowski PP: Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91(7):888-891
7. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM: Pathophysiology of anaemia: Focus on the heart and blood vessels. Nephrol Dial Transplant 2000;15(suppl3):14-18
8. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002;282(1)-R166-172
9. Rodgers KE, Xiong S, Steer R, diZerega GS: Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000;18(4):287-294
10. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT: Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100(9):2310-2314
11. Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H: Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003;23(5):287-293
12. Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT, Capecchi M, Corvol P, Bernstein KE: Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 2000;106(11):1391-1398
13. Comte L, Lorgeot V, Volkov L, Alleglaud A, Aldigier JC, Praloran V: Effects of the ACEI enalapril on blood hematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest 1997;27:788-790
14. Macdougall IC: The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999;14(8): 1836-1841
15. Vlahakos DV, Balodimos C, Papachristopoulos V, Vassilakos P, Hinari E, Vlachojannis JG: Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients. Clin Nephrol 1995;43(1):53-59
16. Haznedaroglu IC, Ozturk MA: Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Bio 2003;35(6):867-880
17. Marusic-Vrsalovic M, Dominis M, Jaksic B, Kusec R: Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol 2003;123(3):539-541
18. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M: Marked species-difference in the vascular angiotensin II-forming pathways: Humans versus rodents. Jpn J Pharmacol 1993;62:207-210
19. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-392
20. Mrug M, Julian BA, Prchal JT: Angiotensin II receptor type 1 expression in erythroid progenitors: Implications for the pathogenesis of postrenal transplant erythrocytosis. Semin Nephrol 2004;24(2):120-130
21. Erturk S, Nergizoglu G, Ates K, Duman N, Erbay B, Karatan O, Ertug AE: The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999;14(8):1912-1916
22. Ducloux D, Saint-Hillier Y, Chalopin JM: Effect of losartan on haemoglobin concentration in renal transplant recipients-a retrospective analysis. Nephrol Dial Transplant 1997;12(12):2683-2686
23. Usalan C, Erdem Y, Caglar M, Altun B, Arici M, Bakkaloglu M, Yasavul U, Turgan C, Caglar S: Effect of enalapril on exaggerated erythropoietin response to phlebotomy in erythrocytosic renal transplant patients. Nephrol Dial Transplant 1998;13(11):2884-2889
24. Vlahakos DV, Marathias KP, Kosmas EN: Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med 2001;134(5):426-427
25. Fakhouri F, Grunfeld JP, Hermine O, Delarue R: Angiotensin-converting enzyme inhibitors for secondary erythrocytosis. Ann Intern Med 2004; 140(6):492-493
26. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K: Hemodilution is common in patients with advanced heart failure. Circulation 2003;107(2):226-229
27. Volpe M, Tritto C, Testa U, Rao MA, Martucci R, Mirante A, Enea I, Russo R, Rubattu S, Condorelli GL, Cangianiello S, Trimarco B, Peschle C, Condorelli M: Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74(5):468-473
28. Biaggioni I, Robertson D, Krants S, Jones M, Haile V: The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994;121:181-186
29. Obayashi K, Ando Y, Terazaki H, Yamashita T, Nakamura M, Ando M: Mechanism of anemia associated with autonomic dysfunction in rats. Autonomic Neuroscience: Basic and Clinical 2000;82:123-129
30. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35(7):1737-1744
31. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001;37(7):1775-1780
32. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107(2):294-299